BCDMH Task Force is assessing interest in the establishment of a voluntary coalition of companies (Consortium) to provide regulatory and technical services to manufacturers, distributors and formulators who are engaged in placing biocidal products on the European market.
The European Halohydantoin (BCDMH) Task Force, with the legal support of Fieldfisher Brussels, is assessing interest in the establishment of a voluntary coalition of companies (Consortium) to provide regulatory and technical services to manufacturers, distributors and formulators who are engaged in placing biocidal products on the European market.
In particular, industry's interest in forming a regulatory coalition is being gauged in relation to substances that either release or generate active bromine (hypobromous acid; HOBr/-OBr) in situ, or biocide active substances containing brominated moieties.
While the substance is currently being scrutinised in the Review Programme under Article 89 of the Biocidal Products Regulation (EU) 528/2012, a CLH proposal for HOBr is also expected to be published in the coming months. Therefore, a significant amount of regulatory activity in relation to HOBr is anticipated in the next 12 to 18 months.
As a coalition member, assistance will be available in matters such as:
- communicating with EU and national authorities;
- acquiring specialised legal advice;
- organising testing strategies, testing and study monitoring;
- preparing risk assessments; and
- managing data and other rights in relation to third-parties.
Being part of a coalition would be particularly beneficial to SME’s, as both the financial and administrative burdens of compliance will be significantly reduced.
If your company would benefit from joining a HOBr Coalition, we kindly ask you to express your interest by Friday, 28 February 2020 by contacting Peter Sellar at: firstname.lastname@example.org.
We will contact all interested parties with further information on the results of this call and potential compliance strategies for HOBr as regulatory procedures continue.